|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1455 PENNSYLVANIA AVENUE, NW |
Address2 | SUITE 925 |
City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 66716-12
|
||||||||
|
6. House ID# 355670000
|
TYPE OF REPORT | 8. Year | 2010 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Steven LaPierre, Vice President Federal Affairs |
Date | 01/14/2011 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
S.660, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies
H.R. 756, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies
S.1380, Medicare Payment Advisory Commission (MedPAC) Reform Act, a bill to make the commission an executive branch agency, and provide the Commission new resources and authority to implement Medicare payment policy
S.301, Physician Payments Sunshine Act, a bill that would require disclosure of the relationships between physicians and the
manufacturers of drugs and devices
H.R. 3138, Physician Payments Sunshine Act, a bill that would require disclosure of the relationships between physicians and
the manufacturers of drugs and devices
H.R. 2502, Comparative Effectiveness Research Act of 2009, a bill to provide for the conduct of comparative effectiveness
research for drugs, devices, and other therapies and create a Comparative Effectiveness Research Trust Fund
S.1213, Patient-Centered Outcomes Research Act of 2009, a bill to provide for the conduct of comparative effectiveness
research for drugs, devices, and other therapies and to establish a Patient-Centered Outcomes Research Trust Fund
H.R. 2824, Doctor-Patient Relationship and Research Protection Act, a bill to support federally funded comparative
effectiveness research for drugs, devices, and other therapies
S.1142, Informed Health Care Decision Making Act, a bill with respect to the inclusion of effectiveness information in drug and
device labeling and advertising
H.R. 4700, the Transparency in All Health Care Pricing Act of 2010, to provide for transparency in health care pricing
H.R. 2249, the Health Care Price Transparency Promotion Act of 2009, to provide for increased price transparency of hospital information and to provide for additional research on consumer information on charges and out-of-pocket costs.
H.R. 4803, the Patients Right to Know Act, to ensure health care consumer and provider access to certain health benefits plan information and to amend title XIX of the Social Security Act to provide transparency in hospital price and quality information
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Medicare Payment Advisory Commission (MedPAC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Steven |
LaPierre |
|
|
|
Michael |
Mattoon |
|
|
|
Scott |
Reid |
|
|
|
Jean |
Frick |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Implementation of H.R. 3590, the Patient Protection and Affordable Care Act, to provide affordable, quality health care for all Americans and reduce the growth in health care spending, and for other purposes.
Implementation of H.R. 4872, the Health Care and Reconciliation Act of 2010, a bill that makes a number of health-related financing and revenue changes to the Patient Protection and Affordable Care Act, specifically regarding the medical device tax.
S.540, Medical Device Safety Act, a bill that would remove federal preemption protection for certain medical devices
H.R.1346, Medical Device Safety Act, a bill that would remove federal preemption protection for certain medical devices
Reform of the 510 (k) regulatory pathway
H.R. 759, Food and Drug Administration Globalization Act, a bill to improve the safety of food, drugs, devices, and cosmetics
S. 882, the Drug and Device Accountability Act, a bill to ensure the safety and quality of medical products and enhance the
authorities of the FDA
H.R. 2502, Comparative Effectiveness Research Act of 2009, a bill to provide for the conduct of comparative effectiveness
research for drugs, devices, and other therapies and create a Comparative Effectiveness Research Trust Fund
S.1213, Patient-Centered Outcomes Research Act of 2009, a bill to provide for the conduct of comparative effectiveness
research for drugs, devices, and other therapies and to establish a Patient-Centered Outcomes Research Trust Fund
H.R. 2824, Doctor-Patient Relationship and Research Protection Act, a bill to support federally funded comparative
effectiveness research for drugs, devices, and other therapies
S.1142, Informed Health Care Decision Making Act, a bill with respect to the inclusion of effectiveness information in drug and
device labeling and advertising
H.R. 3090, Health Equity & Accountability Act of 2009, provides for the elimination of racial and ethnic health disparities
S.660, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies
H.R. 756, National Pain Care Policy Act, a bill to promote greater access to chronic pain therapies
H.R. 4700, the Transparency in All Health Care Pricing Act of 2010, to provide for transparency in health care pricing
H.R. 2249, the Health Care Price Transparency Promotion Act of 2009, to provide for increased price transparency of hospital information and to provide for additional research on consumer information on charges and out-of-pocket costs.
H.R. 4803, the Patients Right to Know Act, to ensure health care consumer and provider access to certain health benefits plan information and to amend title XIX of the Social Security Act to provide transparency in hospital price and quality information.
H.R.1032, Heart Disease Education, Analysis Research, and Treatment for Women Act to amend the Public Health Service Act to improve the prevention, diagnosis, and treatment of heart disease, stroke, and other cardiovascular diseases in women.
S.422, Heart Disease Education, Analysis Research, and Treatment for Women Act to amend the Public Health Service Act to improve the prevention, diagnosis, and treatment of heart disease, stroke, and other cardiovascular diseases in women.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Medicare Payment Advisory Commission (MedPAC)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brenda |
Becker |
|
|
|
Steven |
LaPierre |
|
|
|
Scott |
Reid |
|
|
|
Michael |
Mattoon |
|
|
|
Jean |
Frick |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
S.515. Patent Reform Act of 2009, provisions related specifically to innovative technologies
H.R. 1260, Patent Reform Act of 2009, provisions related specifically to innovative technologies
H.R.5322, Patent and Trademark Office Funding Stabilization Act of 2010, provisions related specifically to innovative technologies
H.R. 4954, to provide recourse under the patent law for persons who suffer competitive injury as a result of false markings
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Mattoon |
|
|
|
Steven |
LaPierre |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
The FY2011 budget proposal and provisions related to the taxation of foreign earnings of U.S. multinational corporations.
S. 3816, Creating American Jobs and Ending Offshoring Act, a bill that would limit deferral for U.S. companies that move production overseas and then import products back to the United States.
S.1203, the GROWTH Act, a bill to extend the research credit through 2010 and to increase and make permanent the alternative
simplified research credit
H.R.4853, Tax Relief, Unemployment Insurance Reauthorization, and Job Creation Act of 2010, a bill that includes extension of the R&D tax credit
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brenda |
Becker |
|
|
|
Steven |
LaPierre |
|
|
|
Michael |
Mattoon |
|
|
|
Scott |
Reid |
|
|
|
Jean |
Frick |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRA
16. Specific lobbying issues
H.R. 4016, the Hazardous Materials Transportation Safety Act of 2009, specifically regarding the transportation of lithium batteries
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Transportation - Dept of (DOT)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Steven |
LaPierre |
|
|
|
Scott |
Reid |
|
|
|
Michael |
Mattoon |
|
|
|
Jean |
Frick |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LBR
16. Specific lobbying issues
S.560, the Employee Free Choice Act, a bill to establish an efficient system to enable employees to form, join, or assist labor
organizations and to provide for mandatory injunctions for unfair labor practices during the organizing efforts
H.R. 1409, the Employee Free Choice Act, a bill to establish an efficient system to enable employees to form, join, assist labor
organizations, and to provide for mandatory injunctions for unfair labor practices during the organizing efforts
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Brenda |
Becker |
|
|
|
Steven |
LaPierre |
|
|
|
Jean |
Frick |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FIN
16. Specific lobbying issues
H.R. 3795, to enact the Over-the-Counter Derivatives Markets Act of 2009, provisions related to changing the regulation on over-the-counter derivatives and how they are used by corporations
H.R.4173, to provide for financial regulatory reform, to protect consumers and investors, to enhance Federal understanding of insurance issues, to regulate over-the-counter derivatives markets, and for other purposes with provisions specifically changing
the regulation on over-the-counter derivatives and how they are used by corporations.
S.3217, The Restoring American Financial Stability Act, on financial reform with provisions on the regulation of over-the-counter derivatives and Congo conflict minerals
Conference Report H. Rept 111-517,Wall Street Reform and Consumer Protection Act, with provisions on the regulation of over-the-counter derivatives
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Michael |
Mattoon |
|
|
|
Steven |
LaPierre |
|
|
|
Jean |
Frick |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code FOO
16. Specific lobbying issues
HR 2749, Food Safety Enhancement Act of 2009, grants FDA the authority and resources to oversee the safety of the nation's food supply. Includes provisions related to registration fees, device import safety fees, and unique identifier provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Steven |
LaPierre |
|
|
|
Michael |
Mattoon |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |